Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to dolutegravir-based versus rilpivirine-based regimens in virologically suppressed, antiretroviral-experienced HIV patients
TCTR20211229003Phase 4Recruiting
- Sponsor
- N/A
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dolutegravir, rilpivirine in human immunodeficiency virus infection (HIV), sponsored by N/A. Started Oct 2021; status: recruiting.
02
Drugs
dolutegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on TCTR20211229003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20211229003.